Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Kumagai, K ^a   Takagi, T ^a   Nakamura, S ^b   Sawada, U ^c   Kura, Y ^c   Kodama, F ^d   Shimano, S ^e   Kudoh, I ^f   Nakamura, H ^g   Sawada, K ^h   Ohnoshi, T ⁱ  

^a CHIBA CANCER CENTER   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e GUNMA CANCER CENTER HOSPITAL   (Japan)

^f Aomori Central Hospital   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h HOKKAIDO UNIVERSITY   (Japan)

ⁱ Japan Lymphoma Treatment Study Group   (Japan)

Author keywords

chemotherapy; HBV carrier; hepatitis B; malignant lymphoma

Indexed keywords

ADOLESCENT; ADULT; AGED; CONFERENCE PAPER; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; INFECTION RISK; JAPAN; LIVER FAILURE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; VIRUS CARRIER;

EID: 8244251413     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S107     Document Type: Conference Paper

References (20)

1. Galbraith RM, Eddleston ALWF, Williams R et al. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528-30.
2. Wands JR. Subacute and chronic active hepatitis after withdrawal of chemotherapy. Lancet 1975; 2: 979 (Letter).
3. Hoofnagle JH, Dusheiko GM, Schafer DF et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-9.
4. Thung SN, Gerber MA, Klion F et al. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985; 145: 1313-4.
5. Pariente EW, Goudeau A, Dubois F et al. Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogenic bone marrow transplantation. Dig Dis Sci 1988; 33: 1185-91.
6. Bird GLA, Smith H, Portman B et al. Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. QJ Med 1989; 73: 895-902.
7. Lau JYN, Lai CL, Lin HJ et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. QJ Med 1989; 73: 911-7.
8. Cherqui D, Girardin MFS, Haioun C et al. Liver transplantation for fulminant hepatitis following chemotherapy for malignant lymphoma. Lancet 1990; 335: 1400.
9. Lau JYN, Bird GLA, Gimson AES et al. Treatment of HBV reactivation after withdrawal of immunosuppression. Lancet 1991; 337: 802.
10. Pinto PC, Hu E, Bernstein-Singer M et al. Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990; 65: 878-84.
11. Lok ASF, Liang RHS, Chiu EKW et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991; 100: 182-8.
12. Ohtsu T, Sai T, Oka M et al. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991; 21: 360-5.
13. Soh LT, Ang PT, Sng I et al. Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer 1992; 28A: 1338-9.
14. Yoshiba M, Sekiyama K, Sugata F et al. Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment. Dig Dis Sci 1992; 37: 1253-9.
15. Yoshiba M, Sekiyama K, Iwabuchi S et al. Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy. Dig Dis Sci 1993; 38: 1751-5.
16. Kumagai K, Takagi T, Sakai C et al. A fatal case of a hepatitis B virus carrier with fulminant hepatic failure after cytotoxic chemotherapy for malignant lymphoma. Jpn J Clin Hematol 1993; 34 (12): 1587-9.
17. Tanosaki R, Okamoto S, Akatsuka N et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine. and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 1994; 74: 1939-44.
18. Omata M, Ehata Y, Yokosuka O et al. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-704.
19. Ehata T, Omata M, Chuang WL et al. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993; 91: 1206-13.
20. Sagnelli E, Manzillo G, Majo G et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2: 395-7.